Omixon Collaborates with G3 and Genomics England to Validate HLA Genotyping from WGS Data

24/09/2014

Omixon has announced a collaboration with the Global Genomics Group (G3) to validate its Target HLA™ software to determine HLA genotypes from whole genome datasets. G3 is providing the whole genome datasets and the corresponding DNA samples of 340 subjects enrolled in the clinical trial called Genetic Loci and...

The Ethics of Preimplantation HLA Testing is Debated at the MEMBS Meeting

14/09/2014

The life of some children with hematological malignancies can be saved by the cord blood of their newborn siblings. Parents may chose to have another child in the hope of conceiving an HLA-identical donor sibling. However, there is only 25% chance that siblings will be perfect HLA-identical and the...

Omixon at This Year’s BSHI Conference

10/09/2014

Arnold Feher and Tim Hague attended the BSHI conference in Manchester. There was a very interesting series of talks about the state of transplantation in the UK, plus a trade show, poster exhibition and some lunchtime presentations from the corporate sponsors concentrating on the use of NGS for HLA....

Cancer Biomarkers

21/08/2014

When tackling any disease, the first step is to learn what signals its presence and what else these signs can mean. In discussing cancer, these signs are referred to as cancer biomarkers. Some organisations define a biomarker as a molecule that the cancerous tumor has secreted into the body,...

Omixon Launches Holotype HLA™ for NGS-based HLA Genotyping

18/07/2014

Omixon announces the launch of Omixon Holotype HLA™ – a combination Assay and Software product that leverages the power of Next Generation Sequencing (NGS), for use on the Illumina® MiSeq sequencing platform. The assay and software have been optimized through cohesive collaboration with the Monos lab at The Children’s...